Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.

ABSTRACT: Platinum drugs are the frontline therapy in many carcinomas, including high-grade serous ovarian cancers. Clinically, high-grade serous carcinomas have an apparent complete response to carboplatin, but tumors invariably recur and response to platinum drugs diminishes over time. Standard of care prohibits re-administration of platinum drugs to these patients who are labeled as having platinum-resistant disease. In this stage patients are treated with non-platinum agents and outcomes are often poor. In vivo and in vitro data presented here demonstrate that this clinical dogma should be challenged. Platinum drugs can be an effective therapy even for platinum-resistant carcinomas as long as they are combined with an agent that specifically targets mechanisms of platinum resistance exploited by

SUBMITTER: La V 

PROVIDER: S-EPMC5551455 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature